Statement of Changes in Beneficial Ownership (4)
March 06 2023 - 04:08PM
Edgar (US Regulatory)
FORM 4
[ ] Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Alloway Paul |
2. Issuer Name and Ticker or Trading
Symbol Homology Medicines, Inc. [ FIXX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
See Remarks |
(Last)
(First)
(Middle)
C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK |
3. Date of Earliest Transaction (MM/DD/YYYY)
3/2/2023
|
(Street)
BEDFORD, MA 01730
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
3/2/2023 |
|
S(1) |
|
10965 (2) |
D |
$1.4467 (3) |
16706 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
The sales reported in this
Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted
by the Reporting Person on September 24, 2022. |
(2) |
This transaction reports the
sale of 10,965 shares which were acquired on February 28, 2023
pursuant to the Issuer's Employee Stock Purchase Plan. |
(3) |
The price reported is a
weighted average price. The securities were sold in multiple
transactions at per share prices ranging from $1.37 to $1.52. The
Reporting Person undertakes to provide upon request the SEC staff,
the Issuer, or any shareholder of the Issuer, full information
regarding the number of securities sold at each separate price
within the range set forth in this footnote 3. |
Remarks:
Chief Legal Officer and Secretary |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Alloway Paul
C/O HOMOLOGY MEDICINES, INC.
ONE PATRIOTS PARK
BEDFORD, MA 01730 |
|
|
See Remarks |
|
Signatures
|
/s/ Paul Alloway |
|
3/6/2023 |
**Signature of Reporting
Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 4(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2023 to Sep 2023
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Sep 2022 to Sep 2023